Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically documented nonsmall-cell lung cancer (NSCLC) presenting as stage IIIB disease without indications for definitive radiotherapy, stage IV disease, or recurrent disease following radiation therapy or surgical resection
No prior chemotherapy, hormonal therapy, immunotherapy, or targeted-therapy-containing regimens for the treatment of NSCLC
Life expectancy of at least 3 months
Eastern Cooperative Oncology Group performance score of 0-1
Adequate bone marrow function
Hemoglobin ≥9.0 g/dL
Absolute neutrophil count ≥1,500/mm\^3
Platelet count ≥100,000/mm\^3
Adequate liver function
Total bilirubin level ≤2.0\*the upper limit of normal (ULN)
Asparate aminotransferase level ≤2.5\*ULN
Alanine aminotransferase level ≤2.5\*ULN
Adequate renal function
Calculated creatinine clearance based on Cockcroft and Gault formula ≥50 mL/min.
You may not be if
Symptomatic central nervous system (CNS) metastasis or active CNS metastasis requiring medication
Malignant body cavity fluid (eg, pleural effusion, cardiac effusion, ascites) that recurred despite appropriate supportive care
Prior radiation of ≥30% of major bone-marrow containing areas (pelvis, lumbar spine)
Documented history of severe autoimmune or immune-mediated symptomatic disease that required prolonged (longer than 2 months) systemic immunosuppressant treatment
Documented history of motor neuropathy considered of autoimmune origin (eg, Guillain Barré syndrome)
Any concurrent malignancy other than nonmelanoma skin cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast, carcinoma of the mucous membrane of the gastrointestinal tract, or superficial bladder cancer treated with systemic therapy
≥Grade 2 diarrhea
History of or concurrent disease of gastrointestinal tract perforations
